Navigation Links
Antibody Technologies and Attrition Rates -- an industry analysis 2013
Date:3/27/2013

enentech, others)
  • In vivo antibody generation technologies (chimeric, primatized, nanobodies, deimmunized, human engineered, humaneered, humanized, XenoMouse,
  • HuMab mouse, KM mouse, VelocImmune mouse, human B-cell derived)
  • Animal species of parental wild-type antibody (mouse, rat, rabbit, hamster, cynomolgus monkey, camelid)
  • Antibody status (active/discontinued)
  • Year of failure
  • Reason for failure (efficacy, pharmacokinetics/ADME; safety; technical, business, next generation, inactivity)
  • Target
  • Immunoglobulin class and IgG isotype
  • Highest phase
  • Therapeutic area of lead indication
  • Companies (developer, licensor/originator)
  • An Antibody Data Sheet was prepared for each unique antibody containing the retrieved information and the source of information in the form of a scientific reference or a hyperlink leading to the website from which the information was obtained.

    The analysis essentially evaluated the question whether there are differences in clinical attrition rates between in vitro and in vivo antibody generation technologies as well as within the different in vitro and in antibody generation technologies. Attrition rate was defined as the percentage of failed antibodies of all active and inactive antibodies.

    Benefits from the data and the analysis:

    • Understand the historical and present state of the art use of antibody technologies;
    • Learn the success rate of each antibody generation technology;
    • Understand the reasons for failure of antibodies in clinical development;
    • Appreciate the relative value of generic and of IP protected antibody technologies;
    • Know which antibody technologies are using your competitors;
    • Know the preferred antibody formats, IgG isotypes, development indications, parental wild-type animal species.

    • '/>"/>

    SOURCE Reportlinker
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. iBio Adds New Therapeutic Antibody to Its Pipeline
    2. Glenmark Announces a New Discovery and the Initiation of IND Enabling Studies of a Novel Monoclonal Antibody Targeting OX40
    3. Monoclonal Antibody Partnering Terms & Agreements Discussed in New Report Now Available at MarketPublishers.com
    4. GeneTex Launches New Antibody Against Phosphorylated Histone H3 for Epigenetics Research
    5. NKT Therapeutics Presents Data on Potential Antibody Treatment for Sickle Cell Disease
    6. Ebola antibody treatment, produced in plants, protects monkeys from lethal disease
    7. Preclinical data shows 100 percent prevention and treatment of influenza with engineered human antibody
    8. Oncobiologics, Inc. Announces a Collaboration Agreement with XOMA Corporation to Utilize XOMAs Fully Human Antibody Libraries for Their Discovery Platform
    9. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
    10. RayBiotech, Inc. and the University of Oslo Enter into Antibody Array Services Collaboration
    11. Sinovac to Present at 55th Annual BioPharma China Convention 2012 - Vaccine & Antibody Focus
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... Texas , Dec. 23, 2014 ... company focused on gynecologic disease, announced today that ... Schuler , Birchview Fund LLC and several Vermillion ... of unregistered shares of Vermillion,s common stock and ... stock in a private placement.  ...
    (Date:12/24/2014)... Fla. , Dec. 23, 2014  Rock Creek ... that it has filed a Clinical Trial Application (CTA) ... Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to ... lead molecule, Anatabine Citrate. Contingent on the ... conduct a Phase I trial to assess the safety, ...
    (Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
    (Date:12/22/2014)... , Dec. 22, 2014 GenomeDx Biosciences today ... Prostate Cancer Classifier, a genomic test for prostate cancer, ... high-risk men managed by radical prostatectomy without adjuvant therapy. ... is relatively uncommon, using tumor genomics to identify these ... disease is an important advance. The study has been ...
    Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3
    ... SAN FRANCISCO, Calif., Sept. 7 Monogram,Biosciences, Inc. (Nasdaq: ... CEO,and Chairman, is scheduled to present a corporate overview ... September 17,2007 at 1:30 p.m. Eastern Time (10:30 a.m. ... California. To access the live audio broadcast or ...
    ... Thursday, October,18, 2007, Wyeth (NYSE: WYE ) will ... will hold a one-hour conference call with,research analysts at ... and others may listen to the call live or ... be accessed by visiting our website,at http://www.wyeth.com ...
    ... Identify microRNA Biomarkers for Overall Survival and Risk ... of Melanoma Metastasizing to Distant Sites, REHOVOT, ... ROSG ), a global leader in the field of,microRNA ... with,NYU Medical Center to leverage the significant potential of microRNA,profiles ...
    Cached Biology Technology:Monogram Biosciences to Present at the ThinkEquity Partners' Fifth Annual Growth Conference 2NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma 2NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma 3NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma 4NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma 5
    (Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
    (Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "Global Facial Recognition Market ... http://photos.prnewswire.com/prnh/20130307/600769 Facial ... of individuals. Facial recognition system measures the overall ... jaw edges, mouth, and the distance between eyes. ...
    (Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
    Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
    ... reason about the natural world? How do they understand ... decades, the consensus was that as young children begin ... stance, favoring humans over non-human animals when it comes ... Northwestern University researchers have taken another look at the ...
    ... Research Fellow at the Department of Medicine, University of Auckland ... and Outcomes Research at Amaris, UK, have been announced as ... The award, an honorarium of 2,000 Euros each, was ... (first authors under the age of 40) that were submitted ...
    ... Hinxton, 10 May 2010 The European Nucleotide Archive ... to become Europe,s primary access point to globally comprehensive ... available from the European Bioinformatics Institute (EMBL-EBI), a part ... DNA sequencing has led to previously unimaginable amounts of ...
    Cached Biology News:Animals talk, sing and act like humans? 2Enabling easy access to DNA sequence information 2
    ...
    Reacts with the 80 kDa fragment of the M-chain of human merosin....
    Mouse anti-JNK (PT183/185) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
    ICAD / DFF45 (NT) Affinity Purified Polyclonal Antibody...
    Biology Products: